First generation leishmaniasis vaccines: a review of field efficacy trials (Q37308029)

19 August 2017

1 reference

title

First generation leishmaniasis vaccines: a review of field efficacy trials (English)

1 reference

19 August 2017

Peter G Smith

4

0 references

Iraj Sharifi

object named as

Iraj Sharifi

7

0 references

Lawrence H. Moulton

object named as

Lawrence H Moulton

5

0 references

Marcel Tanner

12

object named as

Marcel Tanner

1 reference

19 August 2017

11

Marie Paule Kieny

1 reference

19 August 2017

Sassan Noazin

1

1 reference

19 August 2017

Farrokh Modabber

2

1 reference

19 August 2017

Ali Khamesipour

3

1 reference

19 August 2017

Kiumarss Nasseri

6

1 reference

19 August 2017

Eltahir A G Khalil

8

1 reference

19 August 2017

Ivan Dario Velez Bernal

9

1 reference

19 August 2017

Carlos M F Antunes

10

1 reference

19 August 2017

language of work or name

English

0 references

publication date

23 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

26

1 reference

19 August 2017

issue

52

1 reference

19 August 2017

page(s)

6759-6767

1 reference

Leishmaniasis: new approaches to disease control

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

A policy for leishmaniasis with respect to the prevention and control of drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Drug resistance in leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Leishmaniasis: current status of vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Vaccine for prophylaxis and immunotherapy, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Responses to Montenegro antigen after immunization with killed Leishmania promastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

A field trial of a vaccine against American dermal leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Controlled field trials of a vaccine against New World cutaneous leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Vaccination of C57BL/10 mice against cutaneous Leishmaniasis using killed promastigotes of different strains and species of Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Comparative safety and immunogenicity trial of two killed Leishmania Major vaccines with or without BCG in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Stepwise safety trial of a killed Leishmania vaccine in Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major BCG) in children: an extended phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

The predictive validity of naturally acquired delayed-type hypersensitivity to leishmanin in resistance to Leishmania major-associated cutaneous leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-99

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

Second-generation vaccines against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.09.085

10.1016/J.VACCINE.2008.09.085

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference